Is CD39 finally ready for a breakout moment in lung cancer? Innate Pharma tests the thesis
Innate Pharma’s IPH5201 posted encouraging Phase 2 lung cancer data at AACR 2026. Read what it could change for perioperative NSCLC treatment.
Pharma & Biotech